These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 32276920)
1. Molecular docking and ¬in-silico study of natural antagonists of ER-alpha receptor: Potential candidates against breast cancer. Ahmed B; Qadir MI; Noor-Ul-Ain H Pak J Pharm Sci; 2020 Mar; 33(2):733-738. PubMed ID: 32276920 [TBL] [Abstract][Full Text] [Related]
2. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain. Ashtekar SS; Bhatia NM; Bhatia MS Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843 [TBL] [Abstract][Full Text] [Related]
3. Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components. Singla R; Jaitak V Curr Comput Aided Drug Des; 2017 Nov; 13(4):294-302. PubMed ID: 28382865 [TBL] [Abstract][Full Text] [Related]
4. Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective. Saini H; Gupta PK; Mahapatra AK; Rajagopala S; Tripathi R; Nesari T Sci Rep; 2024 Oct; 14(1):23795. PubMed ID: 39394443 [TBL] [Abstract][Full Text] [Related]
5. Insight into estrogenicity of phytoestrogens using in silico simulation. Sugiyama H; Kumamoto T; Suganami A; Nakanishi W; Sowa Y; Takiguchi M; Ishikawa T; Tamura Y Biochem Biophys Res Commun; 2009 Jan; 379(1):139-44. PubMed ID: 19101506 [TBL] [Abstract][Full Text] [Related]
6. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer. Purawarga Matada GS; Dhiwar PS; Abbas N; Singh E; Ghara A; Das A; Bhargava SV J Biomol Struct Dyn; 2022 Aug; 40(13):6183-6192. PubMed ID: 33525984 [TBL] [Abstract][Full Text] [Related]
7. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy. Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor alpha (ER-α) antagonistic activity of phytoconstituents from Potentilla atrosanguinea and Potentilla fulgens in breast cancer. Kumar A; Verma H; Gangwar P; Jangid K; Kumar V; Dhiman M; Jaitak V Fitoterapia; 2024 Sep; 177():106123. PubMed ID: 39004288 [TBL] [Abstract][Full Text] [Related]
9. Computational Screening of Some Phytochemicals to Identify Best Modulators for Ligand Binding Domain of Estrogen Receptor Alpha. Alagarsamy V; Sundar PS; Solomon VR; Murugesan S; Muzaffar-Ur-Rehman M; Kulkarni VS; Sulthana MT; Narendhar B; Sabarees G Curr Pharm Des; 2024; 30(20):1599-1609. PubMed ID: 38698754 [TBL] [Abstract][Full Text] [Related]
10. Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists. Ng HW; Zhang W; Shu M; Luo H; Ge W; Perkins R; Tong W; Hong H BMC Bioinformatics; 2014; 15 Suppl 11(Suppl 11):S4. PubMed ID: 25349983 [TBL] [Abstract][Full Text] [Related]
11. In Silico docking studies of selected flavonoids--natural healing agents against breast cancer. Suganya J; Radha M; Naorem DL; Nishandhini M Asian Pac J Cancer Prev; 2014; 15(19):8155-9. PubMed ID: 25338999 [TBL] [Abstract][Full Text] [Related]
12. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha. Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879 [TBL] [Abstract][Full Text] [Related]
13. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha. Geetha Rani Y; Lakshmi BS J Biomol Struct Dyn; 2019 Mar; 37(5):1189-1203. PubMed ID: 29557271 [TBL] [Abstract][Full Text] [Related]
14. Molecular Docking, Drug-Likeness and ADMET Analysis, Application of Density Functional Theory (DFT) and Molecular Dynamics (MD) Simulation to the Phytochemicals from Withania Somnifera as Potential Antagonists of Estrogen Receptor Alpha (ER- α). Hossain A Curr Comput Aided Drug Des; 2021; 17(6):797-805. PubMed ID: 32748755 [TBL] [Abstract][Full Text] [Related]
17. In silico molecular docking and physicochemical property studies on effective phytochemicals targeting GPR116 for breast cancer treatment. Muthiah I; Rajendran K; Dhanaraj P Mol Cell Biochem; 2021 Feb; 476(2):883-896. PubMed ID: 33106912 [TBL] [Abstract][Full Text] [Related]
18. Phytochemical Profiling, In Vitro and In Silico Anti-Microbial and Anti-Cancer Activity Evaluations and Staph GyraseB and Mohammed HA; Khan RA; Abdel-Hafez AA; Abdel-Aziz M; Ahmed E; Enany S; Mahgoub S; Al-Rugaie O; Alsharidah M; Aly MSA; Mehany ABM; Hegazy MM Molecules; 2021 Jan; 26(3):. PubMed ID: 33499325 [No Abstract] [Full Text] [Related]
19. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies. Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740 [TBL] [Abstract][Full Text] [Related]
20. Potential activity of fevicordin-A from Phaleria macrocarpa (Scheff) Boerl. seeds as estrogen receptor antagonist based on cytotoxicity and molecular modelling studies. Muchtaridi M; Yusuf M; Diantini A; Choi SB; Al-Najjar BO; Manurung JV; Subarnas A; Achmad TH; Wardhani SR; Wahab HA Int J Mol Sci; 2014 Apr; 15(5):7225-49. PubMed ID: 24776765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]